Barry v. Depuy Synthes Companies

Plain English (For Everyone)

Imagine you have a patent for a special way to use a medicine to treat a specific illness. If a company sells that medicine, but the government hasn't approved it for that exact illness, they can't be sued for using your patented method. This is true even if they use the medicine in a way that's very similar to your patent.

For Legal Practitioners

The Federal Circuit affirmed summary judgment of non-infringement, holding that a patent claiming a 'method of treating' a condition with a specific drug is not infringed by a defendant selling that drug if the FDA has not approved the drug for the claimed method. The court also found no infringement under the doctrine of equivalents, emphasizing the lack of FDA approval for the specific method as a critical factor. This ruling reinforces the importance of FDA approval status in method-of-treatment patent infringement cases.

For Law Students

This case tests the boundaries of patent infringement for method-of-treatment claims, particularly concerning the role of FDA approval. The court held that selling a drug, even if it could be used for a patented method, does not constitute infringement if the FDA has not approved the drug for that specific method. This decision highlights the intersection of patent law and regulatory approval, suggesting that lack of FDA approval for the claimed method can be a dispositive factor in non-infringement analysis, even under the doctrine of equivalents.

Newsroom Summary

A federal court ruled that a company cannot be sued for patent infringement over a method of using a drug if the government hasn't approved that specific use. This decision impacts patent holders who claim methods of treatment, potentially limiting their ability to sue drug manufacturers without FDA-approved indications.

Procedural Posture

Plaintiff Barry sued Depuy Synthes for patent infringement. The district court granted summary judgment in favor of Depuy Synthes, finding that Barry's patent claims were invalid as indefinite. Barry appealed this decision to the Federal Circuit.

Constitutional Issues

Patent law - indefiniteness of patent claims

Rule Statements

A patent claim is indefinite if it does not particularly point out the invention.

The scope of a claim must be discernible from the claim language itself.

Parties

• Federal Circuit (party)

Scenario: You developed a unique way to use an existing medication to treat a rare disease, and you have a patent for this method. A pharmaceutical company starts selling that same medication, but the government's health agency (like the FDA) has not officially approved it for treating that specific rare disease. You believe they are infringing your patent.

Your Rights: Based on this ruling, you likely do not have the right to sue the company for patent infringement if the government has not approved the drug for the specific method of treatment you patented. The company's sale of the drug, even if it could be used for your patented method, is not considered infringement in this context.

What To Do: Consult with a patent attorney to understand the specifics of your patent and the drug's regulatory status. While this ruling may limit your options for suing for infringement based on method claims, your attorney can advise on any alternative strategies or related intellectual property protections.

Is it legal for a company to sell a drug that could be used for a patented method of treatment, even if the government hasn't approved that specific use?

Generally, yes. This ruling suggests it is legal for a company to sell a drug for unapproved uses, and they cannot be sued for patent infringement based on a method-of-treatment patent if the government has not approved that specific method. However, the drug manufacturer could still face other regulatory actions or lawsuits related to off-label promotion.

This ruling is from the U.S. Court of Appeals for the Federal Circuit, so it applies to federal patent law across the United States.

For Patent holders of method-of-treatment claims

This ruling significantly narrows the scope of infringement for method-of-treatment patents, especially those involving drugs. Patent holders must now consider the drug's FDA approval status for the claimed method as a critical factor, potentially limiting their ability to enforce their patents against drug manufacturers.

For Pharmaceutical companies

This decision provides a strong defense against method-of-treatment patent infringement claims. Companies can argue non-infringement if the FDA has not approved the drug for the specific method claimed in the patent, reducing their litigation risk in such cases.

Q: What is Barry v. Depuy Synthes Companies about?

Barry v. Depuy Synthes Companies is a case decided by Federal Circuit on January 20, 2026.

Q: What court decided Barry v. Depuy Synthes Companies?

Barry v. Depuy Synthes Companies was decided by the Federal Circuit, which is part of the federal judiciary. This is a federal appellate court.

Q: When was Barry v. Depuy Synthes Companies decided?

Barry v. Depuy Synthes Companies was decided on January 20, 2026.

Q: What is the citation for Barry v. Depuy Synthes Companies?

The citation for Barry v. Depuy Synthes Companies is . Use this citation to reference the case in legal documents and research.

Q: What is the full case name and citation for the Barry v. Depuy Synthes Companies decision?

The full case name is Barry v. Depuy Synthes Companies, Inc. The decision was rendered by the United States Court of Appeals for the Federal Circuit (CAFC). While a specific citation number is not provided in the summary, it is a published opinion from the CAFC.

Q: Who were the parties involved in the Barry v. Depuy Synthes Companies case?

The parties involved were Dr. Michael Barry, the plaintiff and patent holder, and Depuy Synthes Companies, Inc., the defendant. Dr. Barry sued Depuy Synthes for patent infringement.

Q: What was the core dispute in Barry v. Depuy Synthes Companies?

The central dispute revolved around whether Depuy Synthes infringed Dr. Barry's patent for a 'method of treating' a medical condition. Dr. Barry alleged infringement based on Depuy Synthes's sale of a drug, while Depuy Synthes argued their product was not approved for the specific method claimed in the patent.

Q: Which court decided the Barry v. Depuy Synthes Companies case?

The United States Court of Appeals for the Federal Circuit (CAFC) decided the Barry v. Depuy Synthes Companies case. The CAFC affirmed the decision of the lower court, the district court.

Q: What was the nature of Dr. Barry's patent in Barry v. Depuy Synthes Companies?

Dr. Barry's patent claimed a 'method of treating' a specific medical condition. The patent involved the use of a particular drug for this treatment method.

Q: Is Barry v. Depuy Synthes Companies published?

Barry v. Depuy Synthes Companies is a published, precedential opinion. Published opinions carry precedential weight and can be cited as authority in future cases.

Q: What was the ruling in Barry v. Depuy Synthes Companies?

The court ruled in favor of the defendant in Barry v. Depuy Synthes Companies. Key holdings: The court held that a patent claim for a "method of treating" a condition using a specific drug is not infringed by a defendant's product unless that product has been approved by the FDA for the specific method of treatment claimed in the patent.; The court affirmed the district court's finding that the plaintiff's patent claims were not literally infringed because the defendant's drug was not FDA-approved for the claimed method of treatment.; Applying the doctrine of equivalents, the court held that the defendant's product did not infringe the patent claims because the "insubstantial differences" test was not met, as the lack of FDA approval for the claimed method was a substantial difference.; The court rejected the plaintiff's argument that the patent claim was directed to a "new use" of a known compound, finding instead that the claim was directed to a method of treatment.; The court found that the plaintiff failed to demonstrate that the defendant's actions constituted infringement under 35 U.S.C. § 271(e)(2)(A), which governs infringement of patents covering methods of treating human beings..

Q: Why is Barry v. Depuy Synthes Companies important?

Barry v. Depuy Synthes Companies has an impact score of 60/100, indicating significant legal impact. This decision clarifies the intersection of patent law and FDA regulations, particularly for method-of-treatment patents. It emphasizes that for such patents, FDA approval for the specific claimed method is a critical factor in establishing infringement, even under the doctrine of equivalents. This ruling is significant for pharmaceutical companies and patent holders in the life sciences sector.

Q: What precedent does Barry v. Depuy Synthes Companies set?

Barry v. Depuy Synthes Companies established the following key holdings: (1) The court held that a patent claim for a "method of treating" a condition using a specific drug is not infringed by a defendant's product unless that product has been approved by the FDA for the specific method of treatment claimed in the patent. (2) The court affirmed the district court's finding that the plaintiff's patent claims were not literally infringed because the defendant's drug was not FDA-approved for the claimed method of treatment. (3) Applying the doctrine of equivalents, the court held that the defendant's product did not infringe the patent claims because the "insubstantial differences" test was not met, as the lack of FDA approval for the claimed method was a substantial difference. (4) The court rejected the plaintiff's argument that the patent claim was directed to a "new use" of a known compound, finding instead that the claim was directed to a method of treatment. (5) The court found that the plaintiff failed to demonstrate that the defendant's actions constituted infringement under 35 U.S.C. § 271(e)(2)(A), which governs infringement of patents covering methods of treating human beings.

Q: What are the key holdings in Barry v. Depuy Synthes Companies?

1. The court held that a patent claim for a "method of treating" a condition using a specific drug is not infringed by a defendant's product unless that product has been approved by the FDA for the specific method of treatment claimed in the patent. 2. The court affirmed the district court's finding that the plaintiff's patent claims were not literally infringed because the defendant's drug was not FDA-approved for the claimed method of treatment. 3. Applying the doctrine of equivalents, the court held that the defendant's product did not infringe the patent claims because the "insubstantial differences" test was not met, as the lack of FDA approval for the claimed method was a substantial difference. 4. The court rejected the plaintiff's argument that the patent claim was directed to a "new use" of a known compound, finding instead that the claim was directed to a method of treatment. 5. The court found that the plaintiff failed to demonstrate that the defendant's actions constituted infringement under 35 U.S.C. § 271(e)(2)(A), which governs infringement of patents covering methods of treating human beings.

Q: What cases are related to Barry v. Depuy Synthes Companies?

Precedent cases cited or related to Barry v. Depuy Synthes Companies: Warner-Lambert Co. v. Apotex Corp., 316 F.3d 1348 (Fed. Cir. 2003); Merck & Co. v. Integra Lifesciences Int'l Corp., 507 U.S. 197 (2008); Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990).

Q: What was the primary legal reason the Federal Circuit found no patent infringement?

The Federal Circuit found no infringement because Depuy Synthes's product was not approved by the Food and Drug Administration (FDA) for the specific 'method of treating' claimed in Dr. Barry's patent. This lack of FDA approval for the patented method was a critical factor.

Q: Did the Federal Circuit consider the doctrine of equivalents in Barry v. Depuy Synthes Companies?

Yes, the Federal Circuit considered the doctrine of equivalents. However, the court found that even under this doctrine, which allows for infringement when an accused product performs substantially the same function in substantially the same way to achieve substantially the same result, there was no infringement.

Q: What is the significance of FDA approval in patent infringement cases involving methods of treatment?

In cases involving method-of-treatment patents, FDA approval for the specific method claimed is crucial. If the accused product lacks FDA approval for that particular method, it can be a basis for finding no infringement, as demonstrated in Barry v. Depuy Synthes Companies.

Q: How did the court interpret Dr. Barry's patent claims?

The court interpreted Dr. Barry's patent claims as specifically covering a 'method of treating' a condition. The infringement analysis hinged on whether the defendant's actions directly related to and were covered by this specific method claim, particularly in light of FDA approval.

Q: What does it mean for a patent claim to be for a 'method of treating'?

A 'method of treating' patent claim protects a specific process or technique for treating a medical condition. Infringement occurs when someone practices that specific method without authorization. In this case, the method involved using a particular drug.

Q: What is the 'doctrine of equivalents' and how was it applied here?

The doctrine of equivalents allows a patent holder to sue for infringement even if the accused product does not precisely match the patent claims, as long as it performs substantially the same function in substantially the same way to achieve substantially the same result. The CAFC found no infringement under this doctrine in Barry v. Depuy Synthes Companies.

Q: Did the court discuss any specific statutes or regulations in Barry v. Depuy Synthes Companies?

While not explicitly detailed in the summary, the decision heavily implies consideration of the Food, Drug, and Cosmetic Act (FDCA) and related FDA regulations concerning drug approval. The lack of FDA approval for the specific patented method was central to the ruling.

Q: What legal doctrines were considered in Barry v. Depuy Synthes Companies?

The primary legal doctrines considered were patent infringement, specifically concerning method-of-treatment claims, and the doctrine of equivalents. The court also implicitly addressed principles of statutory interpretation related to the Food, Drug, and Cosmetic Act and FDA approval.

Q: What is the burden of proof in a patent infringement case like Barry v. Depuy Synthes Companies?

In a patent infringement case, the plaintiff (Dr. Barry in this instance) bears the burden of proving infringement. This means Dr. Barry had to demonstrate that Depuy Synthes's actions met the criteria for infringement, either literally or under the doctrine of equivalents, which he failed to do.

Q: Could Dr. Barry have pursued a different legal strategy?

Dr. Barry might have explored alternative claims, such as induced infringement or contributory infringement, if evidence supported that Depuy Synthes actively encouraged or supplied a component for use in a way that constituted infringement. However, the core issue remained the lack of FDA approval for the patented method.

Q: How does Barry v. Depuy Synthes Companies affect me?

This decision clarifies the intersection of patent law and FDA regulations, particularly for method-of-treatment patents. It emphasizes that for such patents, FDA approval for the specific claimed method is a critical factor in establishing infringement, even under the doctrine of equivalents. This ruling is significant for pharmaceutical companies and patent holders in the life sciences sector. As a decision from a federal appellate court, its reach is national. This case is moderate in legal complexity to understand.

Q: What is the practical impact of the Barry v. Depuy Synthes Companies decision on pharmaceutical companies?

This decision reinforces the importance of obtaining specific FDA approval for the intended use of a drug, especially when that use is covered by a method-of-treatment patent. Pharmaceutical companies must ensure their product's approved indications align with patented methods to avoid infringement claims.

Q: How does Barry v. Depuy Synthes Companies affect individual doctors or healthcare providers?

For individual doctors and healthcare providers, the decision means they should be mindful of the FDA-approved uses for the drugs they prescribe. Prescribing a drug for a method claimed in a patent, if that method is not FDA-approved for the drug, could potentially lead to legal complications, though the primary focus here was on the manufacturer.

Q: What are the compliance implications for drug manufacturers following this ruling?

Drug manufacturers must carefully align their marketing and sales strategies with the FDA-approved labeling and indications for their products. Selling a drug for a method of treatment that is patented and not FDA-approved for that specific method poses a significant risk of patent infringement.

Q: Who is most affected by the outcome of Barry v. Depuy Synthes Companies?

The parties directly involved, Dr. Barry and Depuy Synthes Companies, are most directly affected. More broadly, pharmaceutical companies developing and marketing drugs, as well as patent holders of method-of-treatment patents, are significantly impacted by the clarity provided on FDA approval's role.

Q: What does this case suggest about the interplay between patent law and FDA regulations?

Barry v. Depuy Synthes Companies highlights the critical intersection of patent law and FDA regulations. It demonstrates that compliance with FDA approval processes is not only a regulatory requirement but also a key factor in determining patent infringement, particularly for method-of-treatment claims.

Q: Does Barry v. Depuy Synthes Companies establish new legal precedent?

While the CAFC affirmed existing principles, the case reinforces the established precedent that a method-of-treatment patent claim is not infringed if the accused product lacks FDA approval for the specific method claimed. It clarifies the application of these principles in the context of drug sales.

Q: How does this case compare to other patent infringement cases involving pharmaceuticals?

This case is similar to other pharmaceutical patent cases where the scope of method-of-treatment claims and the significance of FDA approval are central. It follows a line of reasoning that emphasizes the need for the accused activity to fall within the approved uses of a drug to avoid infringement of such patents.

Q: What was the docket number in Barry v. Depuy Synthes Companies?

The docket number for Barry v. Depuy Synthes Companies is 23-2226. This identifier is used to track the case through the court system.

Q: Can Barry v. Depuy Synthes Companies be appealed?

Potentially — decisions from federal appellate courts can be appealed to the Supreme Court of the United States via a petition for certiorari, though the Court accepts very few cases.

Q: What was the outcome of the Barry v. Depuy Synthes Companies case at the district court level?

The district court granted summary judgment in favor of the defendant, Depuy Synthes Companies. This means the district court found that there were no genuine disputes of material fact and that Depuy Synthes was entitled to judgment as a matter of law, ruling against Dr. Barry's infringement claim.

Q: What was the Federal Circuit's final decision in Barry v. Depuy Synthes Companies?

The Federal Circuit affirmed the district court's decision. This means the appellate court agreed with the district court's ruling that Depuy Synthes did not infringe Dr. Barry's patent.

Q: What legal standard did the Federal Circuit apply when reviewing the district court's decision?

The Federal Circuit reviewed the district court's grant of summary judgment. Summary judgment is reviewed de novo, meaning the appellate court examines the case anew to determine if the district court correctly applied the law and if there were any genuine disputes of material fact.